Vibliome logo Vibliome logo

Vibliome Therapeutics, LLC, has developed a new, systematic approach that enables the design of small molecule Type II kinase inhibitors with unique profiles and a high degree of selectivity

Learn More

down arrow

About Vibliome

Kinases are key regulators of cell function that represent one of the largest and most functionally diverse gene families. There are over 500 kinase enzymes encoded by the human genome which control nearly all cellular functions by phosphorylating proteins and other molecules. Aberrations in these cell signaling pathways affect cell metabolism, division, activation, growth and death, and are hallmarks in the development of cancer as well as other chronic diseases. Kinase inhibitors have been shown to be effective in targeting these aberrant signaling mechanisms that drive disease progression, yet currently-approved inhibitors act against fewer than 40 kinase targets.

In contrast to target-driven high-throughput screening approaches, Vibliome employs a strategy that integrates early profiling of its Type II discovery library against a panel of more than 300 kinase targets. This approach provides a unique SAR database to enable the development of novel Type II kinase inhibitors.

Vibliome is focused on the design of Type II inhibitors that lock kinase targets in an inactive conformation. By analyzing these structures across the kinome, the company has been able to identify unique similarities and differences between kinases that help to tune in selectivity. This structure-guided approach, coupled with the company's novel, annotated Type II kinase inhibitor library, is ideally suited to support precision medicine approaches for cancer and other diseases where selective kinase targeting is needed. Vibliome works with a global network of collaborators to use this approach to develop better medicines for the patients who need them the most.

Our mission to develop new therapeutic options for patients is backed by Deerfield Management in New York, an investment management firm committed to advancing healthcare through investment, information and philanthropy. The Firm works across the healthcare ecosystem to connect people, capital, ideas and technology in bold, collaborative and inclusive ways.

Vibliome Careers

Vibliome’s research operations are located in Bozeman, Montana on the edge of Yellowstone National Park and in the midst of world class skiing, fly fishing, unsurpassed access to nature and Montana’s largest research university.

View Open Positions

Vibliome News

Vibliome Therapeutics Spins Off New Company, Raises Additional Funding

February 24, 2022

Vibliome Therapeutics, LLC, announced today that it has executed an Asset Sale and License Agreement with Beartooth Therapeutics, Inc., for two of its proprietary kinase inhibitor programs against undisclosed targets.

Read More


Vibliome Therapeutics Expands Its Kinase Inhibitor Discovery Library

January 11, 2021

Vibliome Therapeutics, LLC, announced today that it has expanded its highly curated proprietary kinase inhibitor discovery library to more than 500 unique compounds. This library is built on a common chemotype the company is leveraging for the development of novel therapeutics targeting clinically relevant cell signaling pathways.

Read More


Vibliome Therapeutics Closes First Tranche of Its $16 million Series A Financing Round to Advance Selective Kinase Inhibitor Technology for Oncology and Other Disease Applications

April 29, 2019

Vibliome Therapeutics, LLC, announced that it closed a $16mm Series A round of financing to advance its proprietary technology supporting the development of small molecule therapeutics targeting clinically-relevant signaling pathways. Deerfield Management was the sole investor in the Series A financing round and will be providing operational support.

Read More

Vibliome Team


Robert Goodwin, PhD

Chief Executive Officer

LinkedIn logo

James Grenzebach

Chief Operating Officer

LinkedIn logo

Frank Hollinger, PhD

VP Chemoinformatics

LinkedIn logo

Paul Galatsis, PhD

VP Chemistry

LinkedIn logo

Board of Directors

Robert Goodwin, PhD

Chief Executive Officer

Jason Fuller, PhD

Deerfield Management

Cameron Wheeler, PhD

Deerfield Management

Scientific Advisory Board

Keith Flaherty, MD

Associate Professor of Medicine, Harvard Medical School; Director of Clinical Research, Massachusetts General Hospital Cancer Center, Boston, MA

Dejan Juric, MD

Director, Termeer Center for Targeted Therapies & Investigational Cancer Therapeutics Program, and Program Director, Investigational Cancer Therapeutics Program, Massachusetts General Hospital Cancer Center, Boston MA

Eric Springman, PhD

Chief Scientific Officer, Celtaxsys, Inc.

Ken Westover, MD PhD

Associate Professor of Radiation Oncology and Biochemistry, Director of Clinical Innovation and Information Technology, Department of Radiation Oncology, University of Texas Southwestern, Dallas TX

Kwok-Kin Wong, MD, PhD

Anne Murnick Cogan and David H. Cogan Professor of Oncology, Department of Medicine; Director, Division of Hematology and Medical Oncology, New York University Langone Health

533 East Mendenhall St, Bozeman, MT 59715 USA

345 Park Avenue South, New York, NY 10010

+1 (406) 595-3483